Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium

View Full Paper
Ask AI
Bookmark
Share

Authors

AJAndrew JalloukSKSwetha KambhampatiCDChristopher R. D’Angelo

Discussion

Loading...

Member takes

Overview

Cohort study finds median PFS was not reached while cytokine release syndrome occurred in 34.9% of patients.

Key Points

  • To evaluate real-world outcomes and the sequencing of bispecific antibodies in patients with relapsed/refractory follicular lymphoma.
  • Retrospective multicenter observational study across 11 US medical centers
  • Descriptive analyses calculated overall response and complete response rates
  • Cox proportional hazard models assessed progression-free survival and overall survival
  • Among 86 patients, the overall response rate was 86.4% and the complete response rate was 70.4%
  • Cytokine release syndrome occurred in 34.9% of patients with no grade 3 or higher events
  • Patients receiving CAR-T after BsAb had significantly inferior PFS compared to those receiving CAR-T before BsAb

Cite This Study

Jallouk et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0adhttps://doi.org/10.1182/blood-2025-1837
View Full Paper
Ask AI
Bookmark
Share